SAN DIEGO--(BUSINESS WIRE)--PURE Bioscience, Inc. (NASDAQ: PURE), the creator of the patented silver dihydrogen citrate (SDC) antimicrobial, today announced that Chief Executive Officer Michael L. Krall and Chief Financial Officer Peter C. Wulff are scheduled to present to investors at the 5th Annual LD Micro Growth Conference on Thursday, December 6, 2012 at 9:00 a.m. Pacific Time. The conference is being held in Los Angeles, California at the Luxe Sunset Bel Air Hotel.
About PURE Bioscience, Inc.
PURE Bioscience, Inc. develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including Staph (MRSA). PURE’s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today’s global trend toward industry and consumer use of “green” products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver, which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it. PURE is headquartered in El Cajon, California (San Diego metropolitan area). Additional information on PURE is available at www.purebio.com.
Contacts
PURE Bioscience Investor Contact:
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
